The Top 5 Biosimilar Articles for the Week of August 16

Here are the top 5 biosimilar articles for the week of August 16, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 16, 2021.

Number 5: Passage of HR 3 is shaping up as a centerpiece of President Biden's effort to bring pharmaceutical prices under control. If drug companies won't negotiate prices, international reference pricing would kick in.

Number 4: The LAVENDER study demonstrated safety and tolerability of simultaneous intravenous (IV) administration of biosimilar trastuzumab (Kanjinti) and pertuzumab in cohorts of healthy volunteers.

Number 3: A retrospective study of rituximab biosimilars Truxima and Riximyo demonstrated comparable response and survival for patients with diffuse large B-cell lymphoma (DLBCL).

Number 2: When it comes to their willingness to use biosimilars, providers and managed care pharmacists prefer greater transparency on formulary placement and costs, according to a focus group study based on health care surveys.

Number 1: If biosimilars development and sales have lost some of their luster for Pfizer, it’s understandable, given the tremendous boost it received from its COVID-19 vaccine, and the company said its vaccine business is just getting started, with new contracts being signed around the globe.

To read all of these articles and more, visit centerforbiosimilars.com.